Therapy Detail

Therapy Name Fluorouracil + Irinotecan + Leucovorin + Ramucirumab
Synonym Ramucirumab + FOLFIRI
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Fluorouracil Adrucil 5-FU Chemotherapy - Antimetabolite 10 Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth (NCI Drug Dictionary). Fluorouracil is FDA approved for colorectal, breast, stomach, and pancreatic cancer (
Irinotecan Camptosar CPT-11|Onivyde TOPO1 inhibitor 7 Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death (NCI Drug Dictionary). Camptosar (irinotecan) is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (
Leucovorin Wellcovorin Calcium folinate|Calcium citrovorum factor|folinic acid Chemotherapy - Antimetabolite 10 Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (NCI Drug Dictionary).
Ramucirumab Cyramza LY3009806 VEGFR2 Antibody 4 Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant colorectal cancer sensitive Fluorouracil + Irinotecan + Leucovorin + Ramucirumab Phase III Actionable In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855). 25877855
Unknown unknown colorectal cancer not applicable Fluorouracil + Irinotecan + Leucovorin + Ramucirumab FDA approved Actionable In a Phase III trial that supported FDA approval, treatment with a combination of Cyramza (ramucirumab) and the FOLFIRI chemotherapy regimen improved median progression free survival to 5.7 months and overall survival to 11.7 months in patients with metastatic colorectal cancer (PMID: 25877855). 25877855 detail...
Clinical Trial Phase Therapies Title Recruitment Status